These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16697875)

  • 1. Re: treatment delay and prognosis in invasive bladder cancer.
    Masood S; Pietrzak P; Kourief C; Vieira I; Mufti GR
    J Urol; 2006 Jun; 175(6):2364. PubMed ID: 16697875
    [No Abstract]   [Full Text] [Related]  

  • 2. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
    deVere White RW; Katz MH; Steinberg GD
    J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
    [No Abstract]   [Full Text] [Related]  

  • 3. Endpoints of clinical trials for muscle-invasive bladder cancer.
    Tannock IF
    Prog Clin Biol Res; 1990; 353():65-74. PubMed ID: 2217428
    [No Abstract]   [Full Text] [Related]  

  • 4. The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group.
    Kurth K; Denis L; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1992; 378():1-7. PubMed ID: 1301569
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathological variants of invasive bladder cancer according to their suggested clinical significance.
    Lopez-Beltran A; Requena MJ; Cheng L; Montironi R
    BJU Int; 2008 Feb; 101(3):275-81. PubMed ID: 17986288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
    Tran E; Souhami L; Tanguay S; Rajan R
    Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rationale for developing benchmarks for the treatment of muscle-invasive bladder cancer.
    Lee CT
    Urol Oncol; 2007; 25(1):57-65. PubMed ID: 17208141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases.
    Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
    Int J Urol; 2009 Mar; 16(3):293-8. PubMed ID: 19207607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding bladder cancer death: tumor biology versus physician practice.
    Morris DS; Weizer AZ; Ye Z; Dunn RL; Montie JE; Hollenbeck BK
    Cancer; 2009 Mar; 115(5):1011-20. PubMed ID: 19152434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer.
    Weizer AZ; Joshi D; Daignault S; Kinnaman M; Hussain M; Montie JE; Zhang Y; Lee CT
    J Urol; 2007 Apr; 177(4):1287-93. PubMed ID: 17382715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive management of elderly patients with muscle-invasive bladder cancer.
    Weizer AZ; Montie JE; Lee CT
    Nat Clin Pract Urol; 2006 Jul; 3(7):346-7. PubMed ID: 16835604
    [No Abstract]   [Full Text] [Related]  

  • 13. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status of diagnosis and therapy of bladder carcinoma].
    Matz M
    Z Arztl Fortbild (Jena); 1982 Sep; 76(18):815-21. PubMed ID: 6184893
    [No Abstract]   [Full Text] [Related]  

  • 15. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI; Tsolos C; Touloupidis S
    Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
    Tsai HK; Katz MS; Coen JJ; Zietman AL; Kaufman DS; Shipley WU
    Urology; 2006 Dec; 68(6):1188-92. PubMed ID: 17141846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment on: Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.
    Joudi FN
    Eur Urol; 2008 Mar; 53(3):579. PubMed ID: 17804153
    [No Abstract]   [Full Text] [Related]  

  • 18. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
    Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
    Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
    BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality bladder preservation therapy for muscle-invasive bladder tumors.
    Fernando SA; Sandler HM
    Semin Oncol; 2007 Apr; 34(2):129-34. PubMed ID: 17382796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.